Related Experiment Video
Updated: May 10, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?
Günter Niegisch1, Anja Lorch, Michael J Droller
1Department of Urology, Heinrich-Heine-University, Düsseldorf, Germany.
European Urology
|June 19, 2013
Abstract:
Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease.
